Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
they may be reconsidered
MedicalDaily Evidence Check Study type: Phase 3 randomized controlled trial (ATTAIN program) Participants: Adults with obesity or overweight with at least one weight-related comorbidity Approval date: April 1, 2026 What it found: Average weight loss of approximately 12.4% (about 27 lbs) at highest dose over 72 weeks What it did not prove: That it matches injectable GLP-1 efficacy
Alphafold3 modelling of CzNIS1a and the CoNIS1 effector homolog (Yoshino et al., 2012) from Colletotrichum orbiculare revealed the two structures to be remarkably similar (TM-score = 0.95), possibly hinting at them having similar functions ( Figure 6 )
The primary concern is diminished therapeutic effect rather than increased toxicity
Step 6: Do not eat or drink for at least 10 to 15 minutes after dosing
Nutritional intake: Significant appetite suppression associated with GLP-1 therapies can lead to reduced overall dietary intake
US$ 25.94
US$ 28.25
US$ 22.10
US$ 23.75
US$ 26.17
US$ 29.78
